Last reviewed · How we verify
anti drug antibodies dosage
anti drug antibodies dosage is a Biologic drug developed by University Hospital, Rouen. It is currently FDA-approved for Detection and monitoring of anti-drug antibodies in patients receiving biologic therapeutics.
Anti-drug antibodies (ADAs) are immune responses that develop against therapeutic drugs, potentially reducing drug efficacy and increasing clearance.
Anti-drug antibodies (ADAs) are immune responses that develop against therapeutic drugs, potentially reducing drug efficacy and increasing clearance. Used for Detection and monitoring of anti-drug antibodies in patients receiving biologic therapeutics.
At a glance
| Generic name | anti drug antibodies dosage |
|---|---|
| Sponsor | University Hospital, Rouen |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
When patients receive biologic therapeutics (monoclonal antibodies, recombinant proteins, etc.), their immune system may recognize the drug as foreign and generate antibodies against it. These anti-drug antibodies can neutralize the therapeutic agent, accelerate its elimination from circulation, or trigger immune complex formation, thereby diminishing clinical efficacy and potentially causing adverse immunological reactions.
Approved indications
- Detection and monitoring of anti-drug antibodies in patients receiving biologic therapeutics
Common side effects
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (PHASE1)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer (PHASE1, PHASE2)
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti drug antibodies dosage CI brief — competitive landscape report
- anti drug antibodies dosage updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI
Frequently asked questions about anti drug antibodies dosage
What is anti drug antibodies dosage?
How does anti drug antibodies dosage work?
What is anti drug antibodies dosage used for?
Who makes anti drug antibodies dosage?
What development phase is anti drug antibodies dosage in?
Related
- Manufacturer: University Hospital, Rouen — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Detection and monitoring of anti-drug antibodies in patients receiving biologic therapeutics
- Compare: anti drug antibodies dosage vs similar drugs
- Pricing: anti drug antibodies dosage cost, discount & access